MY.Alpha Management HK Advisors Ltd Takes $8.64 Million Position in Zai Lab Limited Unsponsored ADR $ZLAB

Key Points

• MY.Alpha Management HK Advisors Ltd purchased 239,146 shares of Zai Lab Limited Unsponsored ADR, totaling approximately $8,643,000, making it the firm's 10th largest position.
• Insider activity included CEO Ying Du selling 46,387 shares, which decreased their position by 7.95%, while total insider sales over the last ninety days amounted to $7.6 million.
• Zai Lab's stock received mixed analyst ratings, with Wall Street Zen downgrading it to "hold," while Citigroup reaffirmed a "buy" rating with a price target increase to $69.00.

MY.Alpha Management HK Advisors Ltd purchased a new position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 239,146 shares of the company's stock, valued at approximately $8,643,000. Zai Lab comprises 4.3% of MY.Alpha Management HK Advisors Ltd's holdings, making the stock its 10th largest position. MY.Alpha Management HK Advisors Ltd owned approximately 0.22% of Zai Lab as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Oppenheimer Asset Management Inc. purchased a new position in shares of Zai Lab in the 1st quarter worth $603,000. BNP Paribas Financial Markets boosted its stake in shares of Zai Lab by 1,439.8% in the 4th quarter. BNP Paribas Financial Markets now owns 19,755 shares of the company's stock worth $517,000 after buying an additional 18,472 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Zai Lab by 8,090.8% in the 4th quarter. Wells Fargo & Company MN now owns 40,954 shares of the company's stock worth $1,073,000 after buying an additional 40,454 shares during the last quarter. Envestnet Asset Management Inc. purchased a new position in shares of Zai Lab in the 4th quarter worth $976,000. Finally, Northern Trust Corp boosted its stake in shares of Zai Lab by 117.8% in the 4th quarter. Northern Trust Corp now owns 49,365 shares of the company's stock worth $1,293,000 after buying an additional 26,700 shares during the last quarter. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zai Lab news, insider Rafael Amado sold 3,000 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $35.00, for a total value of $105,000.00. Following the completion of the sale, the insider owned 42,178 shares in the company, valued at approximately $1,476,230. This represents a 6.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joshua L. Smiley sold 6,641 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $36.24, for a total value of $240,669.84. Following the completion of the sale, the insider owned 76,604 shares of the company's stock, valued at $2,776,128.96. The trade was a 7.98% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 225,328 shares of company stock worth $7,878,224. 4.96% of the stock is currently owned by corporate insiders.

Zai Lab Trading Up 3.1%

Zai Lab stock traded up $1.05 during trading on Friday, reaching $35.04. The company had a trading volume of 456,200 shares, compared to its average volume of 653,977. Zai Lab Limited Unsponsored ADR has a 52 week low of $17.50 and a 52 week high of $44.34. The firm's 50-day simple moving average is $36.08 and its 200 day simple moving average is $33.76. The firm has a market capitalization of $3.89 billion, a price-to-earnings ratio of -17.18 and a beta of 1.03.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.37). Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%.The business had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. Zai Lab has set its FY 2025 guidance at EPS. On average, analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ZLAB. Citigroup restated a "buy" rating and issued a $69.00 price target (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Wall Street Zen downgraded Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Finally, Leerink Partners set a $75.00 target price on Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $57.22.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.